62 results
F-10
EX-4.11
IPA
ImmunoPrecise Antibodies Ltd
9 Nov 20
Registration of securities (Canada)
8:18am
Therapy to combat the COVID-19 pandemic.
Item 5.
Full Description of Material Change
Please refer to the Company’s news release disseminated on June 29 … manufactured for further testing and possible inclusion in the Company’s PolyTopeTM mAb Therapy to combat the COVID-19 pandemic.
On March 12th, 2020
40FR12B
EX-99.75
IPA
ImmunoPrecise Antibodies Ltd
16 Sep 20
Initial registration of securities (Canada)
4:06pm
Therapy to combat the COVID-19 pandemic.
Item 5.
Full Description of Material Change
Please refer to the Company’s news release disseminated on June 29 … manufactured for further testing and possible inclusion in the Company’s PolyTopeTM mAb Therapy to combat the COVID-19 pandemic.
On March 12th, 2020
40FR12B
EX-99.74
IPA
ImmunoPrecise Antibodies Ltd
16 Sep 20
Initial registration of securities (Canada)
4:06pm
manufactured for further testing and possible inclusion in the Company’s PolyTopeTM mAb Therapy to combat the COVID-19 pandemic.
On March 12th, 2020 … for COVID-19, targeting multiple epitopes on the virus, could prove fundamental in combating this pandemic in an effective and enduring way.”
The Company’s
40FR12B
EX-99.50
IPA
ImmunoPrecise Antibodies Ltd
16 Sep 20
Initial registration of securities (Canada)
4:06pm
Exhibit 99.50
ImmunoPrecise Announces the Launch of PolyTope mAb Therapy™ to Tackle Coronavirus Pandemic
New Approach Entails a Defined Antibody … -announces-the-launch-of-polytope-mab-therapy-to-tackle-coronavirus-pandemic-301022138.html
SOURCE ImmunoPrecise Antibodies Ltd.
View original
40FR12B/A
EX-99.126
IPA
ImmunoPrecise Antibodies Ltd
22 Dec 20
Initial registration of securities (Canada) (amended)
11:05am
lead antibody candidates.
The NRC is supporting this research through the Pandemic Response Challenge Program (PRCP) and the Industrial Research … pandemic. We believe this partnership between the NRC (HHT, PRCP and IRAP) and Zymeworks to have tremendous potential to generate best-in-class SARS
6-K
EX-99.1
o7gsus4jpnzltoatsnm5
14 Mar 22
Immunoprecise Antibodies LTD. 6-K
9:35am
40FR12B
EX-99.76
ohtuoooesv
16 Sep 20
Initial registration of securities (Canada)
4:06pm
40FR12B
EX-99.88
hzrk8l52vuv9h8 td
16 Sep 20
Initial registration of securities (Canada)
4:06pm
F-10
EX-4.5
a1yzncq t0q8e7
9 Nov 20
Registration of securities (Canada)
8:18am
6-K
EX-99.2
lllh0ox2
14 Sep 22
Current report (foreign)
8:31am
40FR12B/A
EX-99.96
0kg lhozjq8
2 Oct 20
Initial registration of securities (Canada) (amended)
2:24pm
40FR12B
EX-99.42
60cgbb1p3dp
16 Sep 20
Initial registration of securities (Canada)
4:06pm
40FR12B/A
EX-99.125
lhv iw8cvn7wrzgb0
22 Dec 20
Initial registration of securities (Canada) (amended)
11:05am
40FR12B
EX-99.80
ih86hb
16 Sep 20
Initial registration of securities (Canada)
4:06pm
40FR12B
EX-99.59
ouyq9
16 Sep 20
Initial registration of securities (Canada)
4:06pm
40FR12B
EX-99.72
x5ihmifrrl73zxfoocv
16 Sep 20
Initial registration of securities (Canada)
4:06pm
6-K
EX-99.1
mtnht diztafy
30 Dec 20
Immunoprecise Antibodies LTD. 6-K
3:27pm
6-K
EX-99.1
pmog6y
9 Sep 21
Ipa FY22 Q1 6-K Filing
8:28am
40FR12B/A
EX-99.91
prnwqurv1yq8jqp
2 Oct 20
Initial registration of securities (Canada) (amended)
2:24pm
40FR12B
EX-99.83
wkv31gb
16 Sep 20
Initial registration of securities (Canada)
4:06pm